2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2434

Promis Tools for Measurement of Patient-Reported Outcomes in Children with Juvenile Arthritis
Abstract Number: 1009

Promoting Professional Development of Medical Educators in Rheumatology: Perspectives of Clinician Scholar Educators
Abstract Number: 1489

Promoting Smoking Cessation Among Rheumatoid Arthritis Patients: What Motivations and Barriers Are Reported after Being Offered a Smoking Cessation Intervention?
Abstract Number: 2334

Proof of Concept Study of the Arthritis Health Journal: An Online Tool to Promote Self-Monitoring in People with Rheumatoid Arthritis (RA)
Abstract Number: 172

Prospective Assessment of Carotid Intima Media Thickness in Relation to Activity of the Disease in Patients with Rheumatoid Arthritis
Abstract Number: 588

Prospective Study about Extension of Dosing Interval with Tocilizumab Therapy in Rheumatoid Arthritis Patients in Remission Maintenance
Abstract Number: 1213

Prospective Study of Dietary Patterns and Risk of Rheumatoid Arthritis in Women
Abstract Number: 5

Prospective Study of the Effect of Treatment with Adalumumab in Angiogenesis in Moderate or Severe Psoriasis for a Period of 6 Months
Abstract Number: 416

Prospective, Standardized, Longitudinal Assessment Reveals Higher Prevalence of Extracutaneous Manifestations in a Pediatric Localized Scleroderma Cohort
Abstract Number: 2572

Protective and Therapeutic Effects of Growth Hormone on Collagen-Induced Arthritis
Abstract Number: 1608

Protective Role of the Vitamin D Receptor Apai (rs7975232) Polymorphism Against Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis from Northern Spain
Abstract Number: 403

Proteinuria in Childhood Onset Lupus Nephritis: When Does It Go Away ?
Abstract Number: 21

Pseudostarvation Using the AMPK Activator Metformin Downregulates Inflammation in Rheumatoid Arthritis Synovial Tissue
Abstract Number: 2520

Psoriatic Arthritis Activity during Pregnancy and the Postpartum� Period
Abstract Number: 2473

Psycho-Socio-Economic Burdens of Childhood Onset Rheumatic Diseases on Families

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].